Drug Effective on Psoriasis in Children
Posted on: Friday, 18 January 2008, 00:00 CST
Etanercept, approved by the U.S. Food and Drug Administration for psoriasis in adults, is safe and effective in reducing psoriasis in pediatric patients.
Lead investigator Dr. Amy Paller of Northwestern University's Feinberg School of Medicine in Chicago said about 7.5 million people in the United States have psoriasis -- a disease in which the immune system causes skin cells to grow at an accelerated rate causing an itchy and painful skin disorder. One-third of psoriasis cases begin in childhood, sometimes infancy.
More than 200 pediatric psoriasis patients from 42 sites in the United States and Canada participated in the 48-week study.
The randomized, double-blind, controlled trial showed 57 percent of patients on etanercept for 12 weeks achieved a 75 percent or greater improvement in symptoms, compared to 11 percent of patients who received a placebo.
A 75 percent improvement is considered the gold standard in psoriasis care, Paller said.
The findings are published in the New England Journal of Medicine.
Source: United Press International
Related Articles
- Surveyed Neurologists in Both the United States and Europe Indicate That a Once-Daily Transdermal Formulation of Levodopa Would Earn a 30 Percent Patient Share in Parkinson's Disease
- For Erectile Dysfunction, Physicians Indicate That Opportunity Exists for Emerging Therapies with Improved Efficacy in Difficult-to-Treat Patient Subpopulations
- Specialists are Highly Satisfied with the Safety and Efficacy of Atripla and Isentress in the Treatment of HIV Patients
- Surveyed Oncologists Indicate that Avastin has Advantages over Temodar/Temodal in Increasing Overall Survival of High-Grade Glioma
- A Drug That Improves Exercise Capacity By a Greater Percentage Than Tracleer Would Earn a 48 Percent Patient Share in the Pulmonary Arterial Hypertension Market
- A Weight Neutral Oral Antidiabetic Drug Would Earn a 25 Percent Patient Share in the Type 2 Diabetes Drug Market
- A Drug With Efficacy Superior to That of Remicade at Inducing Closure and Healing of Fistulas Would Earn a 30 Percent Patient Share in the Crohn's Disease Drug Market
- AstraZeneca's Recentin Plus FOLFOX4 to Earn 10 Percent Patient Share in the Treatment of Colorectal Cancer By 2016
- AstraZeneca's Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer By 2016
- REMICADE Study Demonstrates Significant and Rapid Improvements in the Course of Psoriatic Arthritis; Data Show Promise for Clinical and Structural Damage Improvements in Psoriatic Arthritis
 |
 |
User Comments (0)
RSS Feeds